Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003086387 | SCV003482425 | uncertain significance | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71 | 2022-05-19 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 1150 of the IFT172 protein (p.Met1150Ile). This variant is present in population databases (rs147411312, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with IFT172-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
New York Genome Center | RCV003086387 | SCV003925441 | uncertain significance | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71 | 2022-03-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004985189 | SCV005604273 | uncertain significance | Inborn genetic diseases | 2024-10-24 | criteria provided, single submitter | clinical testing | The c.3450G>A (p.M1150I) alteration is located in exon 31 (coding exon 31) of the IFT172 gene. This alteration results from a G to A substitution at nucleotide position 3450, causing the methionine (M) at amino acid position 1150 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005028227 | SCV005656038 | uncertain significance | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71; Bardet-Biedl syndrome 20 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004738676 | SCV005352749 | uncertain significance | IFT172-related disorder | 2024-04-24 | no assertion criteria provided | clinical testing | The IFT172 c.3450G>A variant is predicted to result in the amino acid substitution p.Met1150Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |